Syndax Pharmaceuticals

General Information

We are a clinical stage biopharmaceutical company developing entinostat as a combination therapy in multiple cancer indications with our initial focus on tumors that have shown sensitivity to immunotherapy, including lung cancer, melanoma, ovarian cancer and triple negative breast cancer, or TNBC. Entinostat is our oral, small molecule drug candidate that has direct effects on both cancer cells and immune regulatory cells, potentially enhancing the body’s immune response to tumors

Employees: 17
Founded: 2005
Contact Information
Address 400 Totten Pond Road, Suite 110, Waltham, MA 02451, US
Phone Number (781) 419-1400
Web Address
View Prospectus: Syndax Pharmaceuticals
Financial Information
Market Cap $208.4mil
Revenues $0.6 mil (last 12 months)
Net Income $-24.1 mil (last 12 months)
IPO Profile
Symbol SNDX
Exchange NASDAQ
Shares (millions): 4.4
Price range $12.00 - $12.00
Est. $ Volume $52.8 mil
Manager / Joint Managers Morgan Stanley/ Citigroup
CO-Managers JMP Securities/ Oppenheimer & Co.
Expected To Trade: 3/3/2016
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change